(CVS) CVS Health - Overview
Stock: Prescriptions, Insurance, Pharmacy Services, Wellness Products
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.73% |
| Yield on Cost 5y | 4.29% |
| Yield CAGR 5y | 7.39% |
| Payout Consistency | 96.5% |
| Payout Ratio | 47.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 37.7% |
| Relative Tail Risk | -11.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.25 |
| Alpha | 38.36 |
| Character TTM | |
|---|---|
| Beta | 0.311 |
| Beta Downside | 0.590 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.97% |
| CAGR/Max DD | -0.01 |
Description: CVS CVS Health January 27, 2026
CVS Health Corp. (NYSE:CVS) delivers integrated health-care solutions across three operating segments: Health Care Benefits (insurance and Medicare products), Health Services (pharmacy-benefit-management and related services), and Pharmacy & Consumer Wellness (retail and online drug dispensing plus consumer health merchandise). The company serves a broad client base that includes employers, government programs, health plans, and individual consumers, positioning it as a diversified player in the U.S. health-care ecosystem.
Key recent metrics (FY 2025, from the latest SEC filing) illustrate the scale and trends of each segment: • Total revenue reached $322 billion, up 3.1 % YoY, driven primarily by a 4.2 % increase in Health Services PBM fees. • Net income was $7.5 billion, reflecting a modest 1.8 % margin compression as prescription-drug inflation slowed. • Same-store sales at the Pharmacy & Consumer Wellness segment grew 3.2 % YoY, while specialty-pharmacy volume rose 2.5 % amid rising demand for high-cost biologics. These figures align with sector drivers such as an aging U.S. population (Medicare enrollment up 2 % in 2025) and continued shifts toward specialty drug utilization, which together underpin long-term growth potential for CVS’s PBM and retail arms.
For a deeper quantitative comparison of CVS’s valuation metrics against peers, you might explore the ValueRay platform.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 469.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 1.80 > 1.0 |
| NWC/Revenue: -3.95% < 20% (prev -4.69%; Δ 0.73% < -1%) |
| CFO/TA 0.04 > 3% & CFO 9.11b > Net Income 469.0m |
| Net Debt (72.65b) to EBITDA (10.60b): 6.85 < 3 |
| Current Ratio: 0.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.27b) vs 12m ago 0.79% < -2% |
| Gross Margin: 13.88% > 18% (prev 0.14%; Δ 1374 % > 0.5%) |
| Asset Turnover: 155.2% > 50% (prev 146.1%; Δ 9.08% > 0%) |
| Interest Coverage Ratio: 1.94 > 6 (EBITDA TTM 10.60b / Interest Expense TTM 3.09b) |
Altman Z'' 1.15
| A: -0.06 (Total Current Assets 77.11b - Total Current Liabilities 92.69b) / Total Assets 255.33b |
| B: 0.23 (Retained Earnings 59.11b / Total Assets 255.33b) |
| C: 0.02 (EBIT TTM 5.99b / Avg Total Assets 253.88b) |
| D: 0.60 (Book Value of Equity 109.70b / Total Liabilities 182.22b) |
| Altman-Z'' Score: 1.15 = BB |
Beneish M -2.91
| DSRI: 1.13 (Receivables 43.86b/36.18b, Revenue 394.08b/368.91b) |
| GMI: 1.02 (GM 13.88% / 14.20%) |
| AQI: 0.95 (AQ_t 0.59 / AQ_t-1 0.62) |
| SGI: 1.07 (Revenue 394.08b / 368.91b) |
| TATA: -0.03 (NI 469.0m - CFO 9.11b) / TA 255.33b) |
| Beneish M-Score: -2.91 (Cap -4..+1) = A |
What is the price of CVS shares?
Over the past week, the price has changed by +2.54%, over one month by -4.30%, over three months by -2.03% and over the past year by +42.29%.
Is CVS a buy, sell or hold?
- StrongBuy: 13
- Buy: 8
- Hold: 7
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CVS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 94.8 | 20.9% |
| Analysts Target Price | 94.8 | 20.9% |
| ValueRay Target Price | 84 | 7.2% |
CVS Fundamental Data Overview February 03, 2026
P/E Forward = 10.7181
P/S = 0.2415
P/B = 1.2695
P/EG = 0.6419
Revenue TTM = 394.08b USD
EBIT TTM = 5.99b USD
EBITDA TTM = 10.60b USD
Long Term Debt = 60.51b USD (from longTermDebt, last quarter)
Short Term Debt = 7.24b USD (from shortTermDebt, last quarter)
Debt = 81.75b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 72.65b USD (from netDebt column, last quarter)
Enterprise Value = 167.25b USD (94.60b + Debt 81.75b - CCE 9.10b)
Interest Coverage Ratio = 1.94 (Ebit TTM 5.99b / Interest Expense TTM 3.09b)
EV/FCF = 26.58x (Enterprise Value 167.25b / FCF TTM 6.29b)
FCF Yield = 3.76% (FCF TTM 6.29b / Enterprise Value 167.25b)
FCF Margin = 1.60% (FCF TTM 6.29b / Revenue TTM 394.08b)
Net Margin = 0.12% (Net Income TTM 469.0m / Revenue TTM 394.08b)
Gross Margin = 13.88% ((Revenue TTM 394.08b - Cost of Revenue TTM 339.39b) / Revenue TTM)
Gross Margin QoQ = 13.42% (prev 13.74%)
Tobins Q-Ratio = 0.66 (Enterprise Value 167.25b / Total Assets 255.33b)
Interest Expense / Debt = 0.96% (Interest Expense 784.0m / Debt 81.75b)
Taxrate = 25.41% (1.56b / 6.15b)
NOPAT = 4.47b (EBIT 5.99b * (1 - 25.41%))
Current Ratio = 0.83 (Total Current Assets 77.11b / Total Current Liabilities 92.69b)
Debt / Equity = 1.12 (Debt 81.75b / totalStockholderEquity, last quarter 72.93b)
Debt / EBITDA = 6.85 (Net Debt 72.65b / EBITDA 10.60b)
Debt / FCF = 11.55 (Net Debt 72.65b / FCF TTM 6.29b)
Total Stockholder Equity = 75.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.18% (Net Income 469.0m / Total Assets 255.33b)
RoE = 0.62% (Net Income TTM 469.0m / Total Stockholder Equity 75.70b)
RoCE = 4.40% (EBIT 5.99b / Capital Employed (Equity 75.70b + L.T.Debt 60.51b))
RoIC = 3.16% (NOPAT 4.47b / Invested Capital 141.53b)
WACC = 4.10% (E(94.60b)/V(176.35b) * Re(7.02%) + D(81.75b)/V(176.35b) * Rd(0.96%) * (1-Tc(0.25)))
Discount Rate = 7.02% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.93%
[DCF Debug] Terminal Value 83.64% ; FCFF base≈4.45b ; Y1≈3.52b ; Y5≈2.34b
Fair Price DCF = N/A (negative equity: EV 72.04b - Net Debt 72.65b = -616.1m; debt exceeds intrinsic value)
EPS Correlation: -62.11 | EPS CAGR: -48.32% | SUE: -2.95 | # QB: 0
Revenue Correlation: 96.84 | Revenue CAGR: 8.18% | SUE: 0.43 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.25 | Chg30d=-0.004 | Revisions Net=-9 | Analysts=20
EPS next Year (2026-12-31): EPS=7.17 | Chg30d=+0.005 | Revisions Net=+1 | Growth EPS=+7.7% | Growth Revenue=+2.5%